Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors

Fig. 2

Comparison of general safety parameters in published RCTs of ICIs and corresponding registration at ClinicalTrials.gov. The order of the categories in each row from left to right: complete match, partial match, not a match, not comparable (due to results missing from CT.gov results, results missing in the published article, or results missing from both sources). The comparison of general safety indicators between the two sources (published trials and corresponding registration) is determined using the approach depicted in Additional file 4: Figure S1

Back to article page
\